
The study aims to estimate the real‐world absolute risk reduction and number‐needed‐to‐treat (NNT) for antenatal corticosteroids at late preterm ages, accounting for gestational age differences between the ALPS and real‐world populations. The study results showed real‐world absolute risk reduction was estimated to be −2.2 cases of respiratory morbidity per 100, compared with −2.8 in the original trial data. Corresponding NNTs were 46 in the real‐world setting vs 35 in the trial. Our focus on absolute measures also highlighted that the benefits of antenatal corticosteroids might be meaningfully greater at 34 weeks vs. 36 weeks. The study concluded that the absolute risk reductions and NNTs associated with antenatal corticosteroid administration at late preterm ages estimated in this study might be more appropriate for patient counselling as they better reflect the anticipated benefits of treatment when used in a real‐world situation.
Like
Save
Share